Exhibit 99.1 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results FORT WORTH, TX – Mar 28, 2024 – TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023. “Over the last several months, we have made significant progress showing th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-4344737 (State or Other Juri ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis - IR, LifeSci Advisors Harlan Weisman - CEO Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Daniel Carlson - Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a remind ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 TFF PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 8 ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Results Conference Call August 15, 2023 11:00 AM ET Company Participants Corey Davis - IR, LifeSci Advisors Dr. Harlan Weisman - CEO Dr. Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Vernon Bernardino - H.C. Wainwright Daniel Carlson - Tailwinds Operator Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) Delaware 82-434 ...

Corporate Investor Presentation May 2023 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions NASDAQ: TFFP 1 Safe Harbor Statement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to______________________ Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) Delaware 82-43 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-4344737 (State or Other Juri ...